DIAGNOS Inc.: NioGold Will Use CARDS 3D Predictor Services for the Malartic Hygrade

BROSSARD, QUEBEC, CANADA--(Marketwire - June 30, 2011) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today a 3D service contract with NioGold Mining Corporation ("NioGold") (TSX VENTURE:NOX). DIAGNOS' CARDS 3D predictor will be used to generated gold targets on the Malartic Hygrade property, part of NioGold's large land holdings in the Malartic mining camp in the Abitibi region, Quebec.

CARDS will be part of a 3D study to develop exploration targets at depth within a highly gold enriched sector of the Malartic camp, which encompasses several gold occurrences as well as the former Camflo mine (Barrick Gold, 1965-92, 8.86Mt @ 5.78 g/t Au). The Malartic Hygrade property is located on trend to the northwest of Marban Block property that is jointly being developed by NioGold and Aurizon Mines Ltd.

This release of CARDS 3D addresses the needs of small and large mining companies alike as they capitalize on their geophysical and geological data and transform it into direct benefit knowledge improving the decision-making.

Benefits

• Open platform: The DIAGNOS CARDS 3D service is complementary to most used 3D systems in the mining industry such as GOCAD, GEMCOM, etc.

• Targeting based on data driven methodology: An objective view of targeting by using complex algorithms that provide an unbiased scientific opinion for geologists.

• Time and money saver: This allows geologists to identify mineralized targets and extensions in a timely manner.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX: ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.